Comunicazione EMA su Uptravi (selexipag) (10/02/2017)
L'Agenzia Europea per i Medicinali (EMA) sta esaminando la sicurezza dei Uptravi (selexipag), a seguito del decesso in Francia di 5 pazienti che assumevano il farmaco.
Italiano
L'Agenzia Europea per i Medicinali (EMA) sta esaminando la sicurezza dei Uptravi (selexipag), a seguito del decesso in Francia di 5 pazienti che assumevano il farmaco.
Faulty Air-In-Line sensor which may generate a false alarm, and cause the syringe pump to stop supplying the infusion to the patient. Interruption of infusion could lead to serious adverse health consequences or death.
Faulty Air-In-Line sensor which may generate a false alarm, and cause the syringe pump to stop supplying the infusion to the patient. Interruption of infusion could lead to serious adverse health consequences or death.
Particulate matter has the potential to block blood vessels, provoke an immune reaction, and/or lead to microinfarcts which could be life threatening.
Particulate matter has the potential to block blood vessels, provoke an immune reaction, and/or lead to microinfarcts which could be life threatening.
Supplements containing ephedrine alkaloids pose a risk of serious adverse events, including heart attack, stroke, and death.
Supplements containing ephedrine alkaloids pose a risk of serious adverse events, including heart attack, stroke, and death.
Reactions can occur within minutes of exposure, and may include wheezing or difficulty breathing; swelling of the face; hives that can quickly progress to more serious symptoms; severe rash; or shock, a life-threatening condition.
Reactions can occur within minutes of exposure, and may include wheezing or difficulty breathing; swelling of the face; hives that can quickly progress to more serious symptoms; severe rash; or shock, a life-threatening condition.
The affected product may cause serious adverse health consequences such as internal tears and perforation to arteries or veins, excessive bleeding, and death.
80.211.154.110